JAMA Editor’s Summary

Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

Editor's Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue

September 17, 2013

Listen on your favorite player Take me to this show’s page

Newer →

Effects of an insulin pump suspension function on hypoglycemia in T1DM, a new decision rule for subarachnoid hemorrhage, and more.

← Older

Pentoxifylline for alcoholic hepatitis, incentivizing hypertension control, P4P and CV quality of primary care, and more.

Facebook Twitter Buffer LinkedIn WhatsApp

Trials of aliskiren for CAD and otamixaban for NSTE-ACS, chronic care management for substance dependence, and more.

Editor’s Audio Summary by Phil B. Fontanarosa, MD, MBA, Executive Editor, the Journal of the American Medical Association, for the September 18, 2013 issue